The aim of this study was to assess the efficacy of a 12-month prevention program conducted in 42 community pharmacies in reducing the risk for diabetes.
and lasted until January 2014. Ethical approval was obtained from the Freiburg Ethics Commission International.
Eligible study subjects had an increased risk for diabetes according to a German Finnish Diabetes Risk Score (FINDRISC) $7 and were at least 35 years old. Exclusion criteria were pregnancy, diabetes, cancer, and participation in a clinical trial 30 days before enrollment. After screening with the FINDRISC, written informed consent was obtained.
The results refer to changes between baseline and the 12-month follow-up measurement. Pharmacists assessed waist and hip circumference, height, weight in a nonfasting state in light clothes, postprandial capillary plasma glucose level, and blood pressure according to standard operating procedures (8) (9) (10) . The FINDRISC, a selfdeveloped demographic and behavior questionnaire, and the 12-item Short Form Health Survey (SF-12) quality-oflife instrument were completed.
All participants received written information about a healthy diet and physical activity. Control group participants were assessed and informed about their health status but did not receive any further counseling.
The intervention group received three individual counseling sessions and five group-based lectures (program GLICEMIA). In the individual counseling, diet and physical activity were discussed and recorded in an individual prevention journal. At the second and third appointment, goal attainment was monitored by the pharmacists, and new personal objectives were agreed on. The five accompanying group-based lectures lasted 75-90 min and covered the following topics: diabetes and risk factors, healthy diet, physical activity, psychological aspects of behavior change, and maintenance of a healthy lifestyle. All participants were informed that the study aimed to prevent diabetes, but they did not know what the outcome measures were.
Study Outcomes
The primary outcome was change in FINDRISC after 12 months. Secondary end points were weight reduction, changes in blood pressure, self-reported physical activity, and quality of life.
Statistical Analysis
An intention-to-treat analysis was performed, imputing missing values using the last observation carried forward method. An additional sensitivity analysis was performed on the completer sample. To investigate the efficacy of the intervention on the primary and secondary end points, we applied linear mixed-effects regression, taking into account the cluster structure of the data and differences between groups at baseline. As a response variable, we used the change in outcome between baseline and 12 months. In a fixedeffects model, we included the grouping variable (intervention vs. control) and possible confounders from baseline, whereas the corresponding community pharmacy was included as a random effect. The resulting adjusted effect size for the grouping variable with corresponding 95% CIs are reported for both primary and secondary end points.
RESULTS
Of the 42 community pharmacies in this study, 40 completed the trial (Supplementary Data). Two pharmacies in the intervention group dropped out due to illness and insolvency. A total of 1,140 participants were recruited (565 in the intervention group and 575 in the control group). The drop-out rate was 13.0% (n = 148). Participants were excluded from the analysis if they did not fulfill the inclusion criteria or if the pharmacy became insolvent (Supplementary Fig. 1) . Thus, 530 participants in the intervention group and 562 in the control group were analyzed, including 115 (10.5%) for whom the missing end points were imputed through the last observation carried forward method due to dropout. In the overall sample, 68.6% of the participants were female (n = 749), and the mean age was 57.5 6 11.3 years. Comparisons of baseline characteristics between the groups in Supplementary Table 1 show significant differences for age, BMI, FINDRISC, physical activity, and physical quality of life as well as for sex, family status, and employment. The proportion of participants who were overweight at baseline was 84.7% in the intervention group (449 of 530) and 79.3% in the control group (445 of 561).
For the primary end point, we found a significant effect of the intervention. The mean change of the FINDRISC after 1 year was a reduction of 20.55 6 1.84 points in the intervention group and an increase in the control group of 0.17 6 1.64 points (Table 1) . After adjusting for the cluster structure and differences in baseline characteristics (sex, age, BMI, employment, level of education), improvement in the FINDRISC in the intervention group was 0.74 (95% CI 0.42-1.04) points above the control group. Data are mean 6 SD (follow-up -baseline) unless otherwise indicated. BP, blood pressure; QOL, quality of life. *Adjusted through a linear mixedeffects models for sex, age, BMI at baseline, employment, and level of education (fixed effects) and for corresponding community pharmacy (random effect). †One missing value in the control group. ‡Three missing values in the intervention group and two in the control group.
Overall, a reduction of the FINDRISC was reached by 39.1% of the intervention group and 21.0% of the control group (x 2 test P , 0.001). The analysis of secondary outcomes (Table 1) showed an adjusted effect on weight loss of 21.57 kg (95% CI 22.23 to 20.90) in the intervention group compared with the control group. Physical activity and physical quality of life improved significantly more among participants in the intervention group. No differences were found for blood pressure and mental quality of life. The sensitivity analysis of the completer sample led basically to the same results as the intention-to-treat analysis (Supplementary Table 2) .
During the trial, diabetes was diagnosed in seven participants in the intervention group and eight in the control group. At the third appointment, three participants in the intervention group and five in the control group had clinically meaningful high plasma glucose levels (fasting $7.0 mmol/L, postprandial $11.1 mmol/L). All were referred to their primary care physician.
CONCLUSIONS
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